Toleranzia AB Total Liabilities
Toleranzia AB total liabilities. Based on the latest financial reports, Toleranzia AB (TOL) has total liabilities worth Skr9.54 Million SEK (≈ $1.03 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See defensive interval ratio of Toleranzia AB to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Toleranzia AB (2012–2024)
Total liabilities of Toleranzia AB from 2012 to 2024. This chart illustrates how Toleranzia AB's total liabilities have evolved over time, based on quarterly financial data.
Toleranzia AB Competitors by Total Liabilities
The table below lists competitors of Toleranzia AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sejoong Co. Ltd
KQ:039310
|
Korea | ₩15.13 Billion |
|
GigaMedia Limited
F:GIFN
|
Germany | €3.82 Million |
|
Antilles Gold Ltd
AU:AAU
|
Australia | AU$1.01 Million |
|
Inter-M Corporation
KQ:017250
|
Korea | ₩48.45 Billion |
|
Picogram Co. Ltd.
KQ:376180
|
Korea | ₩19.63 Billion |
|
Carboclor
BA:CARC
|
Argentina | AR$9.69 Billion |
|
Picard Medical, Inc.
NYSE MKT:PMI
|
USA | $18.76 Million |
|
Vertice Bhd
KLSE:7240
|
Malaysia | RM24.24 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Toleranzia AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Toleranzia AB's balance sheet.
Liquidity & Leverage Metrics
Toleranzia AB Total Liabilities Ratios Explained
Toleranzia AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Toleranzia AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Toleranzia AB (2012–2024)
The table below shows the annual total liabilities of Toleranzia AB from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr6.40 Million ≈ $688.74K |
-7.37% |
| 2023-12-31 | Skr6.91 Million ≈ $743.52K |
+12.84% |
| 2022-12-31 | Skr6.12 Million ≈ $658.93K |
+43.59% |
| 2021-12-31 | Skr4.26 Million ≈ $458.91K |
-8.33% |
| 2020-12-31 | Skr4.65 Million ≈ $500.64K |
+26.95% |
| 2019-12-31 | Skr3.66 Million ≈ $394.37K |
+30.76% |
| 2018-12-31 | Skr2.80 Million ≈ $301.59K |
+33.09% |
| 2017-12-31 | Skr2.11 Million ≈ $226.61K |
-5.39% |
| 2016-12-31 | Skr2.23 Million ≈ $239.52K |
-20.67% |
| 2015-12-31 | Skr2.81 Million ≈ $301.95K |
+97.90% |
| 2014-12-31 | Skr1.42 Million ≈ $152.58K |
+48.89% |
| 2013-12-31 | Skr952.25K ≈ $102.48K |
-47.33% |
| 2012-12-31 | Skr1.81 Million ≈ $194.57K |
-- |
About Toleranzia AB
Toleranzia AB (publ), a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate in clinical trial for treating myasthenia gravis, an autoimmune nerve and muscle disease. The company also develops TOL3 drug candidate for the treatment of ANCA vasculitis, an autoimmune blood vessel disease. In … Read more